Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on May 27, 2021, regarding events occurring on May 26 and May 27, 2021. The filing addresses significant changes in corporate leadership following the death of the company's Chairman and Chief Executive Officer.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Departure of CEO: Dr. Gary Wilcox, Chairman of the Board and Chief Executive Officer, passed away on May 26, 2021.
- Appointment of Interim Leadership: On May 27, 2021, the Board appointed James Martin (Chief Financial Officer) and Sam Lee (President) as co-Interim Chief Executive Officers, effective immediately.
- Board Election: Richard C. Pfenniger, Jr. was elected as a director to fill the vacancy on the Board, effective immediately.
Outlook, Risks, and Management Commentary
The filing includes biographical information for the new director, Richard C. Pfenniger, Jr., highlighting his extensive experience as an interim CEO and board member in the healthcare and education sectors. The company confirmed there were no related party transactions or undisclosed arrangements regarding Mr. Pfenniger's selection. A press release detailing these matters is included as Exhibit 99.1.
Key Facts for Investor Verification
- Confirmation of the transition to co-Interim CEO leadership under James Martin and Sam Lee.
- Review of the new board composition following the election of Richard C. Pfenniger, Jr.
- Assessment of potential strategic shifts or operational impacts resulting from the sudden loss of the CEO and Chairman.
- Verification of the company's succession planning and stability measures in the immediate aftermath of the event.